Hugel, Inc. (KOSDAQ:145020)

Market Cap	1.94T -36.9%
Revenue (ttm)	479.57B +18.9%
Net Income	157.98B +8.4%
EPS	14,402.61 +10.5%
Shares Out	10.80M
PE Ratio	12.50
Forward PE	14.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,413
Open	181,900
Previous Close	182,800
Day's Range	179,500 - 182,400
52-Week Range	175,500 - 308,500
Beta	0.56
Analysts	Buy
Price Target	338,764.71 (+88.2%)
Est. Earnings	Nov 6, 2026

About Hugel

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 620
• Stock Exchange: KOSDAQ
• Ticker Symbol: 145020

Financial Performance

In 2025, Hugel's revenue was 425.11 billion, an increase of 13.96% compared to the previous year's 373.05 billion. Earnings were 140.87 billion, an increase of 3.72%.

Analyst Summary

According to 17 analysts, the average rating for 145020 stock is "Buy." The 12-month stock price target is ₩338,765, which is an increase of 88.20% from the latest price.

Price Target

₩338,765

(88.20% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 12, 2026

Data Sources Report a data error